Immunology Product Guide » Immune System Disorders

Texas Sinus Center offers FinESS Sinus Treatment to break the cycle of chronic sinusitis

Jim Marino — Thu, 21 Jan 2010 07:37:30 +0000

The Texas Sinus Center announced it is now offering the FinESS® Sinus Treatment, a minimally invasive treatment that breaks the cycle of chronic sinusitis (CRS) at Foundation Surgical Hospital of San Antonio. Developed by Minnesota-based Entellus® Medical, Inc., FinESS is an effective treatment that results in less pain, bleeding and recovery time for patients. In most cases, patients are back to their normal routine within hours.

For the full story, Click Here

Pharma firms to conduct H1N1 vaccine human trials in India

Jim Marino — Wed, 23 Dec 2009 10:05:28 +0000

In indigenous swine flu vaccine is far from ready but India has given the green signal to two foreign pharmaceutical giants to begin human trials of their vaccine in the country. According to the health ministry, India has already placed orders for more than one million doses of swine flu vaccines from GSK and Novartis. But before that is administered, the government wants to ensure that the vaccines are absolutely safe.

For the Full Story, Click Here

New H1N1 vaccination clinics open

Jim Marino — Wed, 02 Dec 2009 10:44:46 +0000

Madison and the University of Wisconsin are continuing their push to vaccinate students and a targeted group of community members against the swine flu by offering new H1N1 vaccine clinics in the next few weeks. Public Health-Madison and Dane County will be offering H1N1 clinics at six locations in Madison. The vaccines will be given to pregnant women, people who live with or care for infants less than six months old.

Earlier exposure to flu viruses makes people immune to H1N1 influenza

Jim Marino — Wed, 11 Nov 2009 12:32:38 +0000

Scientists at University of California, Davis, have found that earlier exposure to the seasonal flu viruses provide people with some level of immunity to the 2009 H1N1 influenza virus. In their study, the researchers identified a group of immunologically important sites on the 2009 H1N1 influenza virus that are also present in other influenza viruses that have been circulating for years. The study has been published in the journal of Emerging Infectious Diseases.

The FDA approves Stelara

Jim Marino — Wed, 30 Sep 2009 06:32:01 +0000

The FDA has approved a new biologic drug called Stelara for the treatment of moderate to severe plaque psoriasis in adults. Plaque psoriasis is an immune system disorder that results in the rapid overproduction of skin cells. According to the FDA, about 6 million people in the US have plaque psoriasis, which is characterized by thickened patches of inflamed, red skin, often covered with silvery scales.

Study links fatigue during radiotherapy to pro-inflammatory cytokine network

Jim Marino — Wed, 09 Sep 2009 04:11:45 +0000

Lead researcher Dr Julie Bower, an associate professor in the Department of Psychology and Psychiatry at the University of California, Los Angeles has found that patients who experience fatigue during radiotherapy might be reacting to the activation of the pro-inflammatory cytokine network, a known inflammatory pathway. In a study conducted on 20 people, the researchers discovered that increases in serum markers of cytokine activity, specifically IL-1 receptor antagonist and C-reactive protein, were also linked with fatigue.

Vitamin Boosts Immunity Against Skin Cancer

Jim Marino — Tue, 09 Dec 2008 06:42:16 +0000

According to new research from the University of Sydney, Nicotinamide (VitB3), a vitamin found in common foods like meats, nuts, grains and cereals, may provide the next advance in skin cancer prevention. Presenting the results of a trial to the Clinical Oncological Society of Australia’s Annual Scientific Meeting, Associate Professor Diona Damian said tests had shown the vitamin prevented damage from ultraviolet (UV) radiation by protecting the immune system. The tests on volunteers using nicotinamide both as a lotion and in tablet form offered equally strong protection, against both UVB and UVA.

New Type Of Vaccines Deliver Stronger And Faster Immune Response

Jim Marino — Tue, 02 Dec 2008 10:55:36 +0000

A new vaccine principle is being developed by scientists at the University of Copenhagen which if it works to its full expected potential could help to save millions of lives and revolutionise current vaccine technology. The ‘InVacc’ platform, as it is known, represents an advance on the original DNA vaccines and generates new vaccines with greatly enhanced properties. The platform consists of a chain of amino acids attached to a gene of the virus being vaccinated against.

Everythingantiaging.com announces LimuZ Nei from Immune Tree

Jim Marino — Mon, 17 Nov 2008 13:11:13 +0000

www.Everythingantiaging.com has added LimuZ Nei from Immune Tree to their online catalog of nutritional supplements. LimuZ Nei is a blend of 5 all natural ingredients including Colostrum, limu with Fucoidan, zeolite and acetyl-L-carnitine. It is specifically designed to treat the immune, endocrine, nervous and anti-aging systems. LimuZ Nei has the same electrolyte balance as the blood in our bodies. This balance makes LimuZ Nei highly absorbable allowing for immediate delivery into the body systems because it bypasses the digestive process.

FDA nod to Tibotec’s PREZISTA for treating HIV-1 infection

Jim Marino — Thu, 30 Oct 2008 05:08:36 +0000

The U.S. Food and Drug Administration has expanded the indication for Tibotec Pharmaceuticals’ PREZISTA (darunavir) tablets once-daily dosing as a part of the HIV combination therapy in adult patients who have not taken medication for HIV before. Also, PREZISTA has been approved as a twice-daily for use in adults with a prior experience of treatment. With this approval, the protease inhibitor when administered with 100 mg PREZISTA/r (ritonavir) and other ARVs (antiretroviral agents) can be used for the treatment of HIV-1 infection.